- Home
- RIGL vs RSVR Comparison
RIGL vs RSVR Comparison
Compare RIGL & RSVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | RSVR |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 493.9M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | RSVR |
|---|---|---|
| Price | $29.36 | $10.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $45.67 | $11.50 |
| AVG Volume (30 Days) | ★ 313.7K | 65.6K |
| Earning Date | 05-05-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 19.48 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | $10.95 |
| Revenue Next Year | $12.75 | $4.16 |
| P/E Ratio | ★ $1.48 | $77.14 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $16.88 | $6.97 |
| 52 Week High | $52.24 | $10.32 |
Technical Indicators
Market Signals| Indicator | RIGL | RSVR |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 58.60 |
| Support Level | $28.08 | $7.33 |
| Resistance Level | $30.59 | $10.23 |
| Average True Range (ATR) | 1.13 | 0.29 |
| MACD | -0.22 | -0.04 |
| Stochastic Oscillator | 16.16 | 73.97 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.